New research studies surrounding the medication Retatrutide , specifically the 120 milligram formulation ZPHC ZPHC, indicate a significant impact on body mass decrease and linked health illnesses . Researchers posit that this combined agonist , targeting both GLP-1 and GIP pathways , has the potential to provide a noteworthy advance in the approac